Nanobac Life Sciences Inc announced that it exercised its right to take over the marketing and sales activity of its proprietary nanobiotic regimen from Pegasus Worldwide Inc.
The company also announced that the International Journal of Pathophysiology accepted for publication the manuscript entitled "Calcification in Coronary Artery Disease can be reversed by EDTA - Tetracycline long-term chemotherapy" (DOI 10.1016/ J.Pathophys. 2004.06.001). The manuscript presents compelling data about the potential reversal of coronary artery calcification.
Supported by the International Journal of Pathophysiology manuscript, Nanobac will implement an ambitious and strategic sales and marketing effort for the nanobiotic through its wholly owned subsidiary, Nanobac Sciences. The Company anticipates recognizing revenue from this new sales initiative in the current quarter and also would expect strong sales growth over the next eighteen months.
Alex Edwards, Nanobac's president & CEO, stated, "The acceptance of this paper for publication in a peer reviewed journal is an important milestone; coupled with the clinical data we announced on April 27, it adds to the scientific foundation we are building to better understand the nature and role of nanobacteria in pathological calcification, as well as its detection and treatment."
Edwards continued, "While we are retaining our focus on further defining the cause and effect relationship between Nanobacteria and vascular calcification, as well as other human diseases associated with pathological calcification, we are now positioned to pursue a combination diagnostic and therapeutic solution and anticipate immediate revenue from a new sales initiative for the nanobiotic."
Nanobacteria are associated with pathologic calcification in a variety of degenerative diseases including atherosclerosis (hardening of the arteries) and coronary heart disease.
Nanobacterium sanguineum (nanobacteria) is the smallest self-replicating organism ever detected - at 50 to 500 billionths of a meter, 1/1000th the size of the smallest previously known bacteria.
Nanobac Life Sciences Inc is involved in detection and eradication of Nanobacterium sanguineum (nanobacteria).